Tsuneya Ikezu, MD, PhD

Ikezu photoProfessor, Departments of Pharmacology & Experimental Therapeutics and Neurology

Phone: 617-414-2658
Fax: 617-414-2649
Email: tikezu@bu.edu
Location: L-606 B
Background

Dr. Tsuneya Ikezu completed his undergraduate education at University of Tokyo School of Science and Arts, Japan. He earned his M. D. in 1991 and Ph.D. degrees from University of Tokyo School of Medicine in 1997. He joined the Boston University School of Medicine’s Department of Pharmacology and Experimental Therapeutics with a joint appointment in the Department of Neurology in 2010 as a Professor. Dr. Ikezu also leads the Laboratory of Molecular Neurotherapeutics. He joined the BU ADC in March 2011.

Research Interests
Dr. Ikezu’s research interests are focused on the role of neuroinflammation in the pathophysiology of dementia and as a potential therapeutic target of Alzheimer’s disease, HIV-associated dementia, and more recently chronic traumatic encephalopathy and encephalomyelopathy. He also studies enzymes that induce phosphorylation and aggregation of neurological disease-associated proteins, such as Alzheimer’s disease, HIV-associated dementia, and frontotemporal dementia.

ADC Role
Dr. Ikezu facilitates basic and translational research on neuroinflammation-related neurodegenerative disorders for BU ADC.

Awards/Memberships
Dr. Ikezu is a past recipient of the Vada Oldfield Alzheimer’s Research Award in 2000, the UNMC Distinguished Scientist Award in 2009, and the UNeMed Research Innovation Award in 2009. He serves on several editorial boards, including PLoS One.

Recent Publications
Jun G, Asai H, Zeldich E, Drapeau E, Chen C, Chung J, Park JH, Kim S, Haroutunian V, Foroud T, Kuwano R, Haines JL, Pericak-Vance MA, Schellenberg GD, Lunetta KL, Kim JW, Buxbaum JD, Mayeux R, Ikezu T, Abraham CR, Farrer LA. PLXNA4 is associated with Alzheimer disease and modulates tau phosphorylation. Ann Neurol. 2014 76(3):379-92.

Ikezu S, Ikezu T. Tau-tubulin kinase. Front Mol Neurosci. 2014 7:33.

Asai H, Ikezu S, Woodbury ME, Yonemoto GM, Cui L, Ikezu T. Accelerated neurodegeneration and neuroinflammation in transgenic mice expressing P301L tau mutant and tau-tubulin kinase 1. Am J Pathol. 2014 184(3):808-18.

Freilich RW, Woodbury ME, Ikezu T. Integrated expression profiles of mRNA and miRNA in polarized primary murine microglia. PLoS One. 2013 N8(11):e79416.

Woodbury ME, Ikezu T. Fibroblast growth factor-2 signaling in neurogenesis and neurodegeneration. J Neuroimmune Pharmacol. 2014 9(2):92-101

Frost JL, Le KX, Cynis H, Ekpo E, Kleinschmidt M, Palmour RM, Ervin FR, Snigdha S, Cotman CW, Saido TC, Vassar RJ, St George-Hyslop P, Ikezu T, Schilling S, Demuth HU, Lemere CA. Pyroglutamate-3 amyloid-β deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse  models. Am J Pathol. 2013 183(2):369-81.

McKee AC, Stern RA, Nowinski CJ, Stein TD, Alvarez VE, Daneshvar DH, Lee HS, Wojtowicz SM, Hall G, Baugh CM, Riley DO, Kubilus CA, Cormier KA, Jacobs MA, Martin BR, Abraham CR, Ikezu T, Reichard RR, Wolozin BL, Budson AE, Goldstein LE, Kowall NW, Cantu RC. The spectrum of disease in chronic traumatic encephalopathy. Brain. 2013 136(Pt 1):43-64.

Varnum MM, Ikezu T. The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer’s disease brain. Arch Immunol Ther Exp (Warsz). 2012 60(4):251-66.

Vanderweyde T, Yu H, Varnum M, Liu-Yesucevitz L, Citro A, Ikezu T, Duff K, Wolozin B. Contrasting pathology of the stress granule proteins TIA-1 and G3BP in tauopathies. J Neurosci. 2012 32(24):8270-83.

Goldstein LE, Fisher AM, Tagge CA, Zhang XL, Velisek L, Sullivan JA, Upreti C, Kracht JM, Ericsson M, Wojnarowicz MW, Goletiani CJ, Maglakelidze GM, Casey N, Moncaster JA, Minaeva O, Moir RD, Nowinski CJ, Stern RA, Cantu RC, Geiling J, Blusztajn JK, Wolozin BL, Ikezu T, Stein TD, Budson AE, Kowall NW, Chargin D, Sharon A, Saman S, Hall GF, Moss WC, Cleveland RO, Tanzi RE, Stanton PK, McKee AC. Chronic traumatic encephalopathy in blast-exposed military veterans and a blast neurotrauma mouse model. Sci Transl Med. 2012 4(134):134ra60.

Liu Z, Zhu H, Fang GG, Walsh K, Mwamburi M, Wolozin B, Abdul-Hay SO, Ikezu T, Leissring MA, Qiu WQ. Characterization of insulin degrading enzyme and other amyloid-β degrading proteases in human serum: a role in Alzheimer’s disease? J Alzheimers Dis. 2012 29(2):329-40.

Kiyota T, Ingraham KL, Jacobsen MT, Xiong H, Ikezu T. FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer’s disease and has therapeutic implications for neurocognitive disorders. Proc Natl Acad Sci U S A. 2011 108(49):E1339-48.

Xu J, Tsutsumi K, Tokuraku K, Estes KA, Hisanaga SI, Ikezu T. Actin interaction and regulation of cyclin-dependent kinase 5/p35 complex activity. J Neurochem. 2011 Jan; 116(2): 192-204. [PDF]

Flaherty DP, Kiyota T, Dong Y, Ikezu T, Vennerstrom JL. Phenolic bis-styrylbenzenes as β-amyloid binding ligands and free radical scavengers. J Med Chem. 2010 Nov 25; 53(22): 7992-9. [PDF]

Kiyota T, Okuyama S, Swan RJ, Jacobsen MT, Gendelman HE, Ikezu T. CNS expression of anti-Inflammatory cytokine interleukin-4 attenuates Alzheimer’s disease-like pathogenesis in APP+PS1 bigenic mice. FASEB J. 2010 Aug; 24(8): 3093-102.[PubReader]

Xu J, Sato S, Okuyama S, Swan RJ, Jacobsen MT, Strunk E, Ikezu T. Tau-tubulin kinase 1 enhances pre-fibrillar tau aggregation, spatial learning impairment, and motor neuron degeneration in P301L FTDP-17 tau mutant mice. FASEB J. 2010 Aug; 24(8): 2904-15. [PDF]

Tokuraku K, Marquardt M, Ikezu T. Real-time imaging and quantification of amyloid-beta peptide aggregates by novel quantum-dot nanoprobes. PLoS One 2009 Dec 30; 4(12): e8492. [PDF]

Kiyota T, Yamamoto M, Xiong H, Lambert MP, Klein WL, Gendelman HE, Ransohoff RM, Ikezu T. CCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction. PLoS One 2009 Jul 10;4(7):e6197. [PDF]

Kiyota T, Yamamoto M, Schroder B, Jacobsen MT, Swan RJ, Lambert MP, Klein WL, Gendelman HE, Ransohoff RM, Ikezu T. AAV1/2-mediated CNS Gene Delivery of Dominant-negative CCL2 Mutant Suppresses Gliosis, beta-amyloidosis, and Learning Impairment of APP/PS1 Mice. Mol Ther. 2009 May; 17(5): 803-9.[PDF]

Sato S, Xu J, Okuyama S, Martinez LB, Walsh SM, Jacobsen MT, Swan R, Schlautman JD, Ciborowski P, Ikezu T. Spatial learning impairment, enhanced Cdk5/p35 activity, and down-regulation of NMDA receptor in transgenic mice expressing tau-tubulin kinase 1. J Neurosci. 2008 Dec 31; 28(53): 14511-21. [PDF]

Yamamoto M, Ramirez SH, Sato S, Kiyota T, Cerny RL, Kaibuchi K, Persidsky Y, Ikezu T. Phosphorylation of Claudin-5 and Occludin by Rho Kinase in Brain Endothelial Cells. Am J Pathol 2008 Feb; 172(2): 521-33. [PDF]

Yamamoto M, Kiyota T, Walsh SM, Liu J, Kipnis J, Ikezu T. Cytokine-mediated inhibition of fibrillar amyloid- peptide degradation by human mononuclear phagocytes. J Immunol. 2008 Sep 15;181(6):3877-86. [PDF]

Flaherty DP, Walsh SM, Kiyota T, Dong Y, Ikezu T, Vennerstrom JL. Polyfluorinated Styrylbenzene -Amyloid Plaque Binding Ligands. J Med Chem. 2007 Oct 4; 50(20): 4986-92. [PDF]

Gorantla S, Lui J, Sneller H, Dou H, Smith L, Ikezu T, Volsky DJ, Poluektova L, and Gendelman HE. Copolymer-1 induces adaptive immune anti-inflammatory glial and neuroprotective responses in a murine model of HIV-1 encephalitis. J Immunol 2007 Oct 1; 179(7): 4345-56. [PDF]

Yamamoto M, Kiyota T, Horiba M, Buescher JL, Walsh SM, Gendelman HE, Ikezu T. Interferon- β and tumor necrosis factor-a regulate amyloid-β plaque deposition and β-secretase expression in Swedish mutant APP transgenic mice. AAm J Pathol. 2007 Feb; 170(2): 680-92. [PDF]